DISCLOSED: 5 Stocks Congress Just Bought (Washington's New Whale)

Chris Marott says he screened for interesting congressional trades by starting with small-cap stocks, rather than the usual MAG 7 names, because small caps were expected to rally hard this year and offered more variety. The first name was BigBear.ai (BBAI), which he framed as a volatile small-cap AI/defense contractor that many retail investors already know. Representative Lisa McClain of Michigan reportedly bought twice in February, and Marott noted the stock’s government-contract exposure and defense/national security angle made the buy interesting, though he was skeptical about the company’s growth trajectory. His critique of BigBear.ai was fundamentally about momentum and fundamentals: revenue growth has not been improving the way investors would want, and losses have been getting larger. …

1. Congressional buys were treated as a screening tool, not a buy signal by themselves.
2. The video intentionally focused on small caps first, then moved to larger-cap names with clearer catalysts.
3. BigBear.ai and Cracker Barrel were presented as volatile, tactical names rather than durable investments.
4. Simply Good Foods was highlighted as an idea with analyst upside, but still missing clear growth acceleration.
5. Eli Lilly was the cleanest bullish setup because the trade aligned with an identifiable FDA / obesity-drug catalyst.
6. Broadcom stood out because multiple lawmakers bought it, but the AI trade still demands very strong execution.

• The speaker suggests congressional buys are only an idea source, but then repeatedly leans on them as meaningful context; the logic is somewhat inconsistent.
• The claim that Lisa McClain’s committee role adds informational value to BBAI is speculative and not demonstrated.
• The Cracker Barrel discussion treats a one-week trade as notable evidence, but that may simply reflect short-term price action rather than insight.
• For Simply Good Foods, strong analyst upside is cited, but the argument does not fully explain why the market has been ignoring that upside.
• The Eli Lilly timing point is suggestive but not proof of any informational advantage; the speaker carefully avoids implication, but the emphasis still invites inference.